Related Experiment Video

Updated: Jun 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Inhibition of p53 DNA binding function by the MDM2 protein acidic domain

Brittany Cross1, Lihong Chen, Qian Cheng

  • 1Molecular Oncology Department, Moffitt Cancer Center, Tampa, Florida 33612, USA.

The Journal of Biological Chemistry
|April 2, 2011
PubMed

Insights

MDM2 inhibits p53 DNA binding via a non-ubiquitination mechanism, altering p53 conformation. This reveals new therapeutic strategies for cancer by combining MDM2 and proteasome inhibitors.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • MDM2 is known to regulate p53 primarily through ubiquitination.
  • Ubiquitination-independent roles of MDM2 in p53 regulation are increasingly recognized.
  • Understanding these alternative mechanisms is crucial for targeted cancer therapies.

Purpose of the Study:

  • To investigate the ubiquitination-independent mechanisms by which MDM2 regulates p53.
  • To elucidate how MDM2 binding affects p53's DNA binding activity and conformation.
  • To explore the therapeutic potential of combining MDM2 and proteasome inhibitors.

Main Methods:

  • In vitro and in vivo assays to assess p53 DNA binding activity.
  • Antibody-based epitope mapping to determine p53 conformational changes.
  • Analysis of interactions between MDM2, p53, ARF, SUV39H1, Nutlin, and Bortezomib.

Main Results:

  • MDM2 directly inhibits p53 DNA binding by inducing a conformational change, independent of ubiquitination.
  • The acidic domain of MDM2 is critical for this conformational change and inhibition.
  • ARF and SUV39H1 binding to MDM2's acidic domain restore p53's wild-type conformation and DNA binding.
  • MDM2 inhibitor Nutlin and proteasome inhibitor Bortezomib synergistically enhance p53 DNA binding and transcriptional activity.

Conclusions:

  • MDM2 regulates p53 through ubiquitination-independent mechanisms involving conformational changes.
  • MDM2-interacting repressors access p53 target promoters via this mechanism.
  • Combination therapy with proteasome and MDM2 inhibitors shows therapeutic promise by enhancing p53 activity.

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...